ETOPOSIDE
Childhood Nodular Sclerosis Classical Hodgkin Lymphoma
Northwestern UniversitySmall moleculePhase 3Dormant
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Childhood Nodular Sclerosis Classical Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM National Cancer Institute (NCI) | Phase 3 | BB |
Inno-206 National Cancer Institute (NCI) | Phase 3 | BB |
Ifosfamide Northwestern University | Phase 3 | BB |
BLEOMYCIN City of Hope Medical Center | Phase 3 | BB |
Vinorelbine National Cancer Institute (NCI) | Phase 3 | BB |
View all 32 →
Same molecule, other indications
ETOPOSIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →